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Abstract: Inhibition of poly(ADP-ribose) polymerase (PARP) is an attractive therapeutic
strategy because of the importance of this pathway in restoring DNA damage. Small-molecule
inhibitors of PARP appear most effective when used to treat tumors with underlying defects
in DNA repair, or when combined with DNA-damaging agents. Veliparib is one of several
recently developed oral inhibitors of PARP currently in clinical trials. This review summarizes
the pharmacology, mechanisms of action, toxicity, and activity of veliparib seen in clinical
trials to date. Also discussed are proposed mechanisms of resistance, potential biomarkers of
activity, and issues regarding patient selection and combination therapies that may optimize
use of this exciting new agent.
Keywords: veliparib, solid tumors, PARP inhibitor, BRCA
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The poly(ADP-ribose) polymerase (PARP) family of proteins consists of over 15
different enzymes, which engage in a variety of cellular functions, including cell
cycle regulation, transcription, and repair of DNA damage.1 PARP-1 is the most
abundant and best characterized protein in this group and is critical to the repair
of single-strand DNA breaks through the base excision repair pathway. Effective
inhibition of PARP-1 leads to the accumulation of single-strand breaks, which
ultimately results in double-strand breaks. Usually such double-strand breaks are
repaired by homologous recombination (HR), but in cells with defective HR, PARP
inhibition can result in chromosomal instability, cell cycle arrest, and subsequent
apoptosis.
The inability of HR to correct double-stranded breaks has been observed in tumors
with mutations in the breast cancer-related genes BRCA1 and BRCA2, which code for
proteins essential for normal HR function. The use of small-molecule PARP inhibitors
to exploit this genetic vulnerability in DNA damage repair is an example of synthetic
lethality, in which the simultaneous inhibition of two pathways leads to cell death,
whereas blocking either pathway alone is not lethal. Encouraging preclinical results
for PARP inhibitors in the treatment of BRCA-mutated tumor cells provided strong
rationale for the clinical testing of these agents in patient populations most likely to
carry these mutations, such as those with breast or ovarian cancer. This therapeutic
strategy has now been validated by the recent US Food and Drug Administration
(FDA)-accelerated approval for the PARP inhibitor olaparib as monotherapy to treat
patients with BRCA-mutated advanced ovarian cancer who have been treated with
three prior lines of chemotherapy.2
This review highlights the development of another PARP inhibitor, veliparib
(ABT-888; AbbVie Pharmaceuticals, Chicago, IL, USA). Concepts general to all
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PARP inhibitors are discussed, with specific attention to how
veliparib is being developed in clinical trials.

Biochemistry and pharmacology
of veliparib
The complete chemical name of veliparib is 2-[(R)-2methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide,
and the chemical structure is shown in Figure 1. Veliparib is
able to potently inhibit both PARP-1 and PARP-2, with Kis
(inhibitory constants) of 5.2 and 2.9 nmol/L, respectively.3
As seen with many PARP inhibitors, this activity is generally
selective, and veliparib does not appear to have substantial
effects on other receptors or ion channels at pharmacologically relevant concentrations.
In a 2009 Phase 0 clinical trial of veliparib in adults with
advanced cancers, patients received single oral doses of 10,
25, or 50 mg veliparib.4 Veliparib showed good oral bioavailability, with peak absorption between 0.5 and 1.5 hours, and
a maximum concentration of 0.45 µM after a single dose of
50 mg. Significant inhibition of PARP levels in both tumor
tissue and peripheral blood mononuclear cells was observed
3–6 hours after administration, with recovery at 24 hours
in both preclinical models and patients. These findings led
to the recommendation of twice-daily (bid) administration,
in order to ensure adequate PARP inhibition over longer
periods of time.
Population modeling from 325 adult patients receiving
veliparib bid in one of four clinical trials showed that this
drug’s pharmacokinetics are best described with a onecompartment model with first-order absorption and elimination.5 Veliparib is predominantly eliminated in the urine
as the unchanged parent drug. This process is facilitated by
drug uptake via the organic cation transporter OCT2 into
the renal tubule. Although mostly eliminated by renal clearance, an estimated 13% of veliparib also undergoes hepatic
metabolism by CYP2D6,6 producing the lactam metabolite
M8, which is a much weaker PARP inhibitor than the parent
compound.7
+ 1

2

1

1
+
Figure 1 Chemical structure of veliparib.
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Dose adjustments of veliparib on the basis of body size,
sex, age, ethnicity, or liver function do not appear routinely
necessary. However, creatinine clearance can affect veliparib
exposures, and modifications should be considered in patients
with impaired renal function. Patients who have certain
CYP2D6 polymorphisms, or who are receiving coadministration of OCT2 inhibitors such as cimetidine, may also be
at risk for poor clearance and a clinically relevant increase
in veliparib exposure.8 However, it is felt that veliparib
has a generally low likelihood for meaningful drug–drug
interactions.9

Mechanisms of action
A comprehensive understanding of the possible mechanisms
of action of PARP inhibitors helps provide rationale for
patient selection and study design. BRCA-mutated tumors are
well established to have inadequate DNA repair machinery,
and so be sensitive to PARP inhibition through the concept of
synthetic lethality. Importantly, HR deficiencies can also be
seen in other contexts as well, including tumors with defects
in the DNA damage sensors ATM (ataxia-telangiectasia
mutated) and ATR (ATM- and RAD3-related protein),10
PTEN mutations,11 or defects in the Fanconi repair pathway.12
This information has been used to expand the rationale for
treatment to include tumors that may have limited capacity
for DNA repair (also termed “BRCAness”) that could predict
the activity of PARP inhibitors.
The genetic knockout of PARP-1 substantially impairs
DNA repair following damage from radiation or cytotoxic
chemotherapy agents;13 accordingly, investigators have
combined PARP inhibitors with conventional cancer treatments known to damage DNA. As will be discussed, this
approach has been or is being investigated with therapeutic
irradiation as well as a wide variety of cytotoxic agents,
including temozolomide, cisplatin, carboplatin, doxorubicin,
paclitaxel, and topotecan.
In addition to these mechanisms of action, PARP inhibitors may also poison DNA by stabilizing PARP-1 and 2 at
sites of DNA damage, generating complexes that may be
even more toxic than the unrepaired single-strand breaks
which result from PARP inhibition. This concept was termed
“PARP trapping” by Murai et al14 and its characterization
impacted PARP inhibitor development in two important
ways. First, this work showed that pathways other than HR
may be essential for repairing the PARP–DNA complexes,
therefore providing rationale for treating tumors with defects
in the FEN1, polymerase β, postreplication repair, and
Fanconi anemia pathways. Secondly, these investigators
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demonstrated a difference between PARP inhibitors in the
ability to trap PARP, despite similarities in the ability to
inhibit PARP catalytic activity. In this regard, veliparib was
inferior to both niraparib and olaparib in trapping PARP.
This finding may be related to the period of time that PARP
is “trapped” onto the DNA, and it could have implications
for dosing and toxicity of the various agents.15

Preclinical activity
Donawho et al3 produced one of the earliest and most complete assessments of the preclinical activity of veliparib,
and showed that veliparib potentiated the activity of temozolomide, cisplatin, carboplatin, and cyclophosphamide in a
variety of tumors, including melanoma, glioma, lymphoma,
colon carcinoma, and breast carcinoma. They also demonstrated that veliparib crosses the blood–brain barrier, providing further rationale for its pairing with temozolomide to
treat intracranial tumors. Further, veliparib also potentiated
the effect of fractionated radiation through its impairment of
both single- and double-strand break repair pathways.
Additional studies have built on these earlier preclinical
observations. Palma et al16 expanded the scope of tumors and
showed combinatorial activity of veliparib and temozolomide
in multiple types of lung cancer as well as in pancreatic and
prostate cancer xenografts. Interestingly, activity was demonstrated in models that had acquired resistance to single-agent
temozolomide, and conventional measures of temozolomide
resistance such as expression of methylguanine methyltransferase (MGMT) or mismatch repair proteins did not
correlate with the degree of sensitivity to the combination
of temozolomide + veliparib. Additional work by Palma
et al16 showed that potentiation of temozolomide toxicity
was dose-dependent and that extended veliparib scheduling
was not more beneficial than limiting administration to be
simultaneous with 5-day courses of temozolomide.17
Lin et al11 further explored genetic predictors of veliparib
in glioblastoma models, demonstrating that veliparib activity
may be greatest in cells with PTEN deficiency, which characterizes up to one-third of gliomas. They also demonstrated the
importance of using doses in laboratory experiments that are
clinically relevant and can achieve serum concentrations that
are feasible in humans, which is a key point also emphasized
by other investigators.18
As mentioned above, PARP inhibitors appear to work in
different ways, including interfering with the repair of DNA
breaks as well as by stabilizing the PARP–DNA complex
and inducing cytotoxicity through PARP trapping. In a recent
article, Murai et al19 reported that synergy with conventional
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cytotoxic agents can be affected by which mechanism of
action is greatest for a particular inhibitor. For example, while
olaparib and veliparib have similar inhibitory effects on PARP
catalytic activity, the degree of PARP trapping is greater with
olaparib. This mechanism appears to be particularly important
when a PARP inhibitor is combined with temozolomide,
as the combination of olaparib + temozolomide has greater
in vitro activity than that of veliparib + temozolomide. However, both inhibitors showed robust synergy in combination
with camptothecin, suggesting that activity with that particular
combination may be mediated more by downregulating direct
PARP catalytic activity.
Several studies have also reported the radiosensitizing
effect of veliparib in a variety of solid tumors,20–23 including
under the hypoxic conditions often found in larger tumors.24
In cultured glioblastoma cells, veliparib enhanced the lethality of radiation, especially in combination with temozolomide. Interestingly, this effect again was seen irrespective of
the MGMT status of the tumor cells.25 Similar combinatorial
efficacy has also been seen with veliparib and radiation
combined with oxaliplatin, 5-fluorouracil, or irinotecan in
cultured colorectal carcinoma cells.26
There have been a limited number of direct preclinical
comparisons between PARP inhibitors. In addition to the
studies reported above, Shen et al27 reported that the newergeneration PARP inhibitor BMN 673 exhibited selective
cytotoxicity and elicited DNA repair biomarkers at much
lower concentrations than olaparib or veliparib. A further
study suggests that PARP inhibitors may vary in their “offtarget” effects, and this may significantly impact their efficacy against certain tumor types. For example, Jelinic and
Levine28 showed that olaparib reduced DNA damage repair
activity via G2 cell cycle arrest in a p53-dependent manner,
an effect not seen with veliparib.
In summary, the preclinical studies provide rationale for
various clinical applications, including the targeting of specific
tumor types and possible therapeutic combinations. These
studies also provide some insight into possible mechanisms of
action and the relative efficacy of different agents, but are ultimately limited somewhat by the artificial nature of the preclinical models used. Only through rigorous clinical trials will the
ultimate utility, or futility, of a particular agent be decided.

Clinical trials
Veliparib has already been studied in a variety of Phase I and
II trials, and currently there are five Phase III trials ongoing.
Results from several reported studies are summarized in
Table 1. To date, there have been no head-to-head clinical
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Table 1 Key published clinical trials with veliparib for treatment of solid tumors
Study

N

Phase

Other agents

Population

Veliparib dose

Comments

Puhalla
et al29

88

1

–

RP2D was
400 mg bid

For 28 patients with mutant BRCA treated
at RP2D, overall response rate was 40%,
with clinical benefit rate of 68%

Coleman
et al30
Rugo
et al34
Somlo
et al35

50

II

–

400 mg bid

26% response rate, well tolerated

71

II

150 mg bid

41

II

Higher rate of pathologic complete response
(2% vs 26%) with veliparib
Encouraging activity seen to single-agent
veliparib

Kummar
et al36
Kunos
et al41
Kummar
et al37

37/38
27

Randomized
II
I/ll

24

1

Carboplatin,
paclitaxel
Veliparib followed
by veliparib +
carboplatin
With/without oral
cyclophosphamide
Topotecan,
growth factor
Topotecan

BRCA-mutated,
platinum-refractory
ovarian or basal-like
breast cancer
Ovarian with
BRCA1/2 mutation
Triple-negative
breast cancer
BRCA-mutated
breast cancer

Su et al38

29

1

Temozolomide

Hussain
et al39
Reiss
et al44
Mehta
et al45

25

Pilot

Temozolomide

Recurrent uterine
cervix cancer
Refractory solid
tumors and
lymphoma
Pediatric brain
tumor
Prostate cancer

22

1

81

1

Whole abdomen
irradiation
Whole brain
irradiation

Peritoneal
carcinomatosis
Brain
metastases

Ovarian cancer

400 mg bid (single
agent); 150 mg bid
(with carboplatin)
60 mg qd
10 mg bid days
1–5
10 mg bid

25 mg/m2 bid
40 mg bid days
1–7
40–160 mg bid
10–300 mg bid
(RP2D was
200 mg bid)

Addition of veliparib did not improve activity
Minimal activity seen with veliparib dose
10 mg bid
Increases in yH2AX in circulating tumor cells
shows PARP inhibition can modulate the
capacity to repair DNA damage
Similar pharmacokinetics in children
Well tolerated but only modestly active
Well tolerated, with some prolonged disease
stability
Well tolerated, with improved efficacy
compared to predicted results from
established nomogram

Abbreviations: RP2D, recommended Phase II dose; bid, twice-daily; qd, once-daily; PARP, poly(ADP-ribose) polymerase.

studies of different PARP inhibitors, which therefore limits
the assessment of how veliparib compares to the six other
agents currently in clinical trials.

Dose-finding and toxicity of single-agent
trials of veliparib
Puhalla et al29 have reported in abstract form the Phase I
trial of veliparib in adults with relapsed cancers, with doses
ranging from 50 to 500 mg bid being studied. They defined
the recommended Phase II dose (RP2D) of single-agent veliparib as 400 mg bid. Given that veliparib has been studied
using tablet strengths of 10 and 40 mg, patients receiving the
RP2D dose will take up to 20 tablets bid, which compares
to 16 tablets bid of olaparib at its RP2D. The toxicity of this
dose is best estimated from a Phase II trial in 50 patients with
ovarian cancer conducted by Coleman et al.30 In that study,
the most common side effects were gastrointestinal, with half
of the patients having nausea of at least grade 2 (46%) or
grade 3 (4%) severity. An additional 18% of these patients
had grade 2 vomiting. In general, gastrointestinal toxicity was
seen primarily in the earlier courses, and was manageable
with aggressive antiemetics, delays, and dose reductions.
Fatigue was seen in one-third of patients, but was generally
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grade 2. Myelosuppression was modest, with only 2% having either grade 3–4 neutropenia or thrombocytopenia. The
median dose intensity was 78%. The overall toxicity profile
seen with veliparib is somewhat similar to that reported in
Phase II trials of other PARP inhibitors such as olaparib. For
example, in a recent trial of 46 women with ovarian cancer
treated with single-agent olaparib, grade 3 fatigue was seen
in 11% of patients.31 While three-fourths of patients experienced nausea, only 26% of patients had grade 2 nausea, and
grade 3 nausea was not reported. Serious late effects such
as secondary leukemia and myelodysplastic syndrome have
occasionally been observed following treatment with PARP
inhibitors,32 although the extensive pretreatment of patients
included in these studies makes attribution of this complication very difficult. However, given that double-strand
breaks may build up in normal tissues following treatment
with PARP inhibitors over time,33 continued surveillance for
second malignancies is reasonable.
Combination trials using veliparib and cytotoxic chemotherapy have used either the full RP2D as above, or lower
dosing, depending in part on the expected toxicity related to
the conventional agent. This has led to a wide range of doses
being studied, as noted in Table 1. In general, no unusual
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toxicities have been encountered in these trials to date,
although myelosuppression may be enhanced when veliparib
is combined with a drug known to cause this effect.

Activity of veliparib in clinical trials
The single-agent Phase I trial conducted by Puhalla et al29
involved 88 patients, and was designed to enrich the population with patients more likely to respond to PARP inhibitors.
Eligibility criteria included patients with BRCA-mutated
tumors as well as those with BRCA-like tumors, such as
serous ovarian cancer and basal-like breast cancer. At the
RP2D, 28 BRCA-mutated patients were evaluable, and the
response rate and clinical benefit rate (complete + partial
responses + stable disease) were 40% and 68%, respectively.
This compares to 4% and 38%, respectively, of patients with
tumors wild-type for BRCA.
Coleman et al30 then performed a Phase II study using
the same dose of 400 mg veliparib bid in patients with
BRCA-mutated ovarian cancer. Of the 50 evaluable patients,
30 (60%) were platinum resistant. The study was designed
to identify with 90% power a response rate of 25%. For all
patients, the response rate was 26%, thus meeting the predefined definition of activity in this multicenter prospective
study. For platinum-resistant and platinum-sensitive patients,
the response rate was 20% and 35%, respectively, (P=0.33).
Another encouraging Phase II result came from the
I-SPY 2 trial for patients with triple-negative breast cancer.34
Patients in the experimental group received veliparib plus
carboplatin and paclitaxel, while the control group was
assigned to standard paclitaxel followed by anthracycline
chemotherapy. Women in the veliparib group were twice
as likely to have a pathologic complete response compared to those receiving standard therapy (52% vs 26%).
Researchers then used this data to calculate a 92% Bayesian
predictive probability that the veliparib regimen would be
statistically superior to standard therapy alone for women
with triple-negative disease in a Phase III trial enrolling
300 patients.
Additional studies combining veliparib with conventional
chemotherapy agents have also been reported. A multicenter
Phase II study recently reported in abstract form by Somlo et al35
involved patients with metastatic BRCA-mutated breast
cancer. Patients received veliparib 400 mg bid daily until
progression, at which time carboplatin was added and the
veliparib dose reduced to 150 mg bid. A partial response rate
of 20% was seen in patients receiving four cycles of singleagent veliparib, and larger trials of veliparib are planned both
alone and in combination with chemotherapy.

OncoTargets and Therapy 2015:8
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Unfortunately, compelling clinical activity has not been
demonstrated in all trials to date. In a randomized Phase II
trial conducted by Kummar et al36 ovarian cancer patients
received the combination of veliparib 60 mg once daily
together with daily oral cyclophosphamide, which had previously been established as the RP2D based on an earlier
Phase I trial of this combination.37 Control patients received
cyclophosphamide alone. While the combination was well
tolerated, there was no improvement seen from the addition
of this dose of veliparib to metronomic administration of
cyclophosphamide.
The combination of veliparib and temozolomide has been
described, although many reports are preliminary. Myelotoxicity can be considerable with this combination, and so
the dose of veliparib is often as low as one-tenth of the usual
single-agent dose. Veliparib doses of 40 mg bid (and an
equivalent dose of 25 mg/m2 in a pediatric trial) together with
temozolomide 150 mg/m2/day for 5 days appear tolerable and
are associated with some extent of disease stabilization in
glioma38 and prostate cancer,39 although minimal activity was
observed for those with refractory hepatocellular carcinoma.40
Other combinations with topotecan have been reported41,42
and continue to be under investigation (Table 2).
In regard to combination studies, a recent preclinical
assessment of PARP inhibitors combined with temozolomide and irinotecan to treat an orthotopic mouse model
of Ewing sarcoma may possibly inform further decisions
about dosing and combination with chemotherapy agents.15
PARP inhibitors are an attractive option for the treatment of
Ewing sarcoma because the characteristic EWS–FLI1 fusion
protein that drives tumor growth interacts with PARP-1
through a proposed positive feedback loop,43 which may
make Ewing sarcoma cells particularly sensitive to PARP
inhibitors in vitro. Although limited single-agent activity in
the orthotopic model was seen from any of the three agents
tested (olaparib, BMN-673, or veliparib), there was synergy
with the combined use of PARP inhibitors + temozolomide,
and especially with the further addition of irinotecan.15
Interestingly, veliparib was the least active of the three
PARP inhibitors at the dosages used, although later testing
of veliparib at higher doses demonstrated both tolerability
as well as similar efficacy to both olaparib and BMN-673.
Although the previous clinical studies mentioned above had
tried to maximize the temozolomide dose while escalating
veliparib dose,38–40 the Ewing sarcoma data would suggest
that the opposite should be done, at least for that tumor type.
It is not clear whether this strategy should be employed when
treating other cancers, although these interesting results do
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Table 2 Key ongoing clinical Phase II or III trials of veliparib in patients with solid tumors
Clinicaltrials.gov
identifier

Phase

Other agents

Population

Phase III
NCT02163694

III (randomized)

Carboplatin, paclitaxel

NCT02106546
NCT02264990

III (randomized)
III (randomized)

Carboplatin, paclitaxel
Carboplatin, paclitaxel

NCT02032277

III (randomized)

Carboplatin, other standard
chemotherapy
Temozolomide

HER2-negative metastatic/unresectable
BRCA-mutated breast cancer
Untreated advanced/metastatic lung cancer
First cytotoxic chemotherapy for metastatic/
advanced non-small-cell lung cancer
Early-stage triple-negative breast cancer

NCT02152982
Phase II
NCT02158507
NCT01585805
NCT01576172
NCT01638546
NCT01506609
NCT01827384
Phase I/ll
NCT01514201
NCT01711541
NCT01351909
NCT01642251
NCT01690598
NCT01489865
NCT01472783

ll/lll (randomized)

Newly diagnosed glioblastoma

II
II (randomized)
II (randomized)
II (randomized)
II
II

Lapatinib
Gemcitabine, cisplatin
Abiraterone/prednisone
Temozolomide
Temozolomide, or carboplatin/paclitaxel
Monotherapy based on genetic testing
(NCI-MPACT study)

Metastatic triple-negative breast cancer
Advanced/metastatic pancreatic cancer
Metastatic hormone-resistant prostate cancer
Relapsed small-cell lung cancer
BRCA-mutated metastatic breast cancer
Advanced solid tumors

I/ll
I/ll
I/ll (randomized)
I/ll (randomized)
I/ll

Temozolomide, radiation
Combination chemotherapy
Cyclophosphamide
Cisplatin, etoposide
Topotecan

I/ll
I/ll

Fluorouracil, oxaliplatin
–

Children with newly diagnosed pontine glioma
Stage IV head and neck cancer
Advanced/metastatic breast cancer
Advanced or metastatic lung cancer
Relapsed ovarian cancer with negative
or unknown BRCA status
Metastatic pancreatic cancer
Relapsed ovarian cancer with BRCA mutation

Abbreviation: NCI-MPACT, National Cancer Institute-Molecular Profiling based Assignment of Cancer Therapeutics.

raise questions when combinatorial therapies fail to produce
the desired level of activity.
Finally, some early trials have investigated the combination of veliparib and therapeutic irradiation. In the Phase I
setting, veliparib was studied with whole abdominal radiation in patients with peritoneal carcinomatosis.44 The highest
studied dose of veliparib (160 mg bid) was well tolerated,
with some suggestion of disease stability seen. When given in
combination with whole-brain radiotherapy for patients with
metastatic cancer, Mehta et al45 reported the dose of 200 mg
bid as the RP2D.

Ongoing clinical trials
As seen in Table 2, clinicaltrials.gov lists at least 19 Phase
II or III trials using veliparib, currently recruiting patients.
These studies include such cancers as breast, prostate, head
and neck, lung, pancreatic, ovarian, colorectal, and glioma.
While many of these studies couple veliparib with conventional cytotoxic chemotherapy, some involve combination
with radiation or other targeted agents such as lapatinib.
The five open Phase III trials are focused on lung cancer,
breast cancer, and glioblastoma. In addition to these, there
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are multiple Phase I trials studying an even broader array of
combinations and tumor types.

Mechanisms of resistance
Although exciting activity has been seen with the use of
PARP inhibitors in treating BRCA-deficient tumors, some
patients still do not respond initially or develop acquired
resistance with continued treatment. There are likely several
potential mechanisms that may explain resistance in these
patients. First, there may be secondary genetic and/or epigenetic events that restore functional HR in tumors that were
once HR deficient.46 Secondary mutations that restore BRCA
protein function and lead to cisplatin resistance have been
reported in patients with recurrent ovarian cancer,47 and such
secondary mutations have been seen in patients who initially
respond but then develop resistance to olaparib.48
Other potential mechanisms of resistance include
somatic mutations of the p53 binding protein TP53BP1,49
which can result in partial restoration in HR. Drug efflux
through transporters such as the multidrug resistance protein
1 (P-glycoprotein) has also been implicated in resistance,
with some suggestion that cotreatment with medications to
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block P-glycoprotein can help reverse resistance to PARP
inhibitors.50 Finally, loss or even reduction of PARP1 expression may also be associated with acquired resistance.51 Further prospective studies of all of these potential mechanisms
may ultimately help identify which patients are most likely
to benefit from PARP inhibition. It is unclear at this point
whether there are specific mechanisms of resistance that differ between individual PARP inhibitors, and no mechanism
to date appears necessarily unique to veliparib.

Potential biomarkers
As discussed above, the hallmark of sensitivity to PARP
inhibition is deficient DNA repair. The most compelling clinical benefit to date in single-agent studies has been in trials
selecting for patients whose tumors have either confirmed or
suspected HR deficiencies, such as BRCA mutations, patients
with BRCA-like tumors such as basal- or triple-negative breast
cancer, or patients who are platinum sensitive. However, it is
clear that a subset of ovarian and breast cancer patients who
lack BRCA mutations can respond to PARP inhibitors, and
so there is no absolute correlation between these predictors
and clinical response.29,52 Other specific genes involved in
the DNA damage response, such as HPIβ, have also been
reported as putative biomarkers of sensitivity to veliparib,
either given alone or in combination with chemotherapy.53
Given the complexity of the DNA repair process and the
complicating factor of tumor heterogeneity, the search for
genetic biomarkers to predict sensitivity to PARP inhibitors
remains quite complicated, such that single biomarker models
may not ultimately prove beneficial.54
PARP expression level and/or PARP activity in tumor
tissue may also play a role in determining the sensitivity to
PARP inhibitors,51 and they are being prospectively studied
in clinical trials. Elevated levels of PAR-related proteins
as assessed by Western blotting or immunohistochemistry
have also been shown to predict sensitivity of human cancer
cells to PARP inhibitors55 and could be another avenue of
investigation in clinical trials.
In acute myeloid leukemia cells, BRCA1 protein levels
inversely correlate with PARP inhibitory activity, with the
majority of cell lines having low BRCA1 levels, presumably
due to posttranscriptional regulatory mechanisms.56 This
raises the possibility that immunostaining of tumors for
BRCA1 could potentially be a useful biomarker, although
this approach has not yet been reported in a clinical trial. One
biomarker combination predicted to be exquisitely sensitive
to PARP inhibitors is high 53BP1 expression coupled with
methylation of BRCA1, although these findings were only
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noted in a small subset of patients with triple-negative breast
cancers.57 It is hoped that further molecular characterization
of tumors using genetic profiling techniques will identify
biomarkers that can be validated in clinical trials, and this
remains a focus of continued research.

Conclusions and challenges ahead
PARP inhibitors represent an exciting demonstration of
the potential for targeted therapy and genetic selection of
patients. The recent FDA approval of olaparib, and the
encouraging data from clinical trials of related compounds
such as veliparib, suggests the worthiness of pursuing this
therapeutic strategy. Many questions remain regarding the
use of these agents, including their proper sequence in
treatment. For example, in ovarian cancer, there is debate
about whether these targeted agents should be used before
or after platinum chemotherapy, in combination with
conventional cytotoxic agents, or as maintenance therapy
for high-risk, genetically susceptible patients following
standard treatment.58 These issues will be better clarified
in the multiple Phase II and III trials, which are already
underway.
Although the PARP inhibitors now in clinical trials
have shown some preclinical differences, especially in the
degree of PARP trapping, the true clinical significance of
these differences is not yet clear. There have been no headto-head clinical trials of different agents in the same class,
and comparisons between trials are complicated. As noted
above, some preclinical studies suggest that veliparib is not
the most robust PARP inhibitor in its class, and in fact there
is now a clinical trial of BMN-673 open for patients with
BRCA1/2-mutated ovarian cancer who have failed other
PARP inhibitors (clinicaltrials.gov identifier NCT02326844).
Nevertheless, the activity and tolerability of veliparib seen
in early phase studies is exciting, and the likelihood of FDA
approval will hinge on the results of the ongoing Phase III
trials. Whether more than one targeted agent in a class will
receive licensure, as occurred with the EGFR inhibitors
erlotinib and gefitinib, remains to be seen.
Substantial challenges lie ahead for the further development of veliparib. For the translational scientist, the
identification of reliable biomarkers will be critical for the
success of this targeted agent. For the clinical scientist,
opportunities exist for expanding veliparib treatment for
tumors beyond those already studied, including for Ewing
sarcoma, 15 lymphoma, 42 and even leukemia.59 Finally,
thoughtful trial design regarding the dosing and sequence
of veliparib and its combination with radiation or other
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chemotherapy agents will be necessary to realize the full
potential of this drug.
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